The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.

Novartis is presented as a solid long-term investment for building a million-dollar retirement portfolio. The pharmaceutical company demonstrates resilience by growing revenue despite patent cliffs, maintains a deep pipeline of 15 billion-dollar brands, and has consistently increased dividends annually since 1996, making it suitable for buy-and-hold investors seeking stability and income.

Novo Nordisk's stock plummeted 16% after its obesity drug CagriSema underperformed in a head-to-head trial against Eli Lilly's tirzepatide, achieving 23% weight loss compared to 25.5%. The setback sent the stock to its lowest point since 2021, with Deutsche Bank downgrading the company from 'Buy' to 'Hold'. Meanwhile, Eli Lilly gained 4.86% as investors reassessed obesity-drug leaders.

PYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer treatment and diagnosis, with multiple radioligands in development.

The Turner Syndrome market is projected to grow from USD 1.93 billion in 2025 to USD 3.67 billion by 2033, with a CAGR of 8.39%. Growth is driven by advances in genomic diagnostics, increased awareness, government-backed rare disease initiatives, and expanding hormone replacement therapies. North America leads with 37.70% market share, while Asia-Pacific is expected to grow fastest at 9.43% CAGR.

Novartis announced final Phase 3 ALIGN study results for Vanrafia (atrasentan), showing the drug slows kidney function decline in adults with IgA nephropathy. The drug demonstrated a 2.39 ml/min/1.73m2 difference in eGFR change versus placebo at Week 136, with stronger results at Week 132. Novartis plans to submit for traditional approval in 2026, building on the accelerated approval received in April 2025.

The global Hepatitis B treatment market is valued at USD 4.52 billion in 2025 and is projected to reach USD 7.74 billion by 2033, growing at a CAGR of 6.97%. Growth is driven by expanded screening programs, increased antiviral therapy adoption, and novel treatment innovations. The U.S. market is expected to grow from USD 1.00 billion to USD 1.54 billion by 2033.

Novartis reported Q4 2025 results with net sales of $13.34 billion, missing consensus estimates, impacted by generic competition and pricing pressures. However, the company demonstrated strong growth in blockbuster therapies like Kisqali (+44%), Kesimpta (+27%), and Pluvicto (+70%). Despite facing its largest patent expiry in history in 2026, management expects low single-digit sales growth and projects adjusted operating income to accelerate in the second half of 2026. Shares rose 1.79% to a new 52-week high.

The Vanguard International High Dividend Yield ETF (VYMI) has surged 41% since the start of 2025, significantly outperforming the S&P 500's 18% gain. The ETF focuses on international dividend-paying companies across developed and emerging markets, offering a 3.4% current yield (averaging 4.1% since early 2025)—more than three times the S&P 500 average. While recommended as a diversification tool, experts suggest keeping the bulk of investments in U.S. stocks (around 90%) with international holdings as a portfolio cushion.

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.